Guardant Health Q3 revenue $265.2M (+39% YoY); raises FY2025 revenue guidance to $965-$970M

Guardant Health, Inc.

2025-Q3 EPS reported -$2.32 revenue$700,755,000

Q3 total revenue $265.2M (+39% YoY); GAAP net loss $92.7M ($0.74/share), non-GAAP net loss $48.3M ($0.39/share).
Oncology revenue $184.4M (+31%), 74K tests (+40%); Shield screening revenue $24.1M (from $1M), 24K tests.
FY2025 revenue guidance raised to $965-$970M (from $915-$925M), ~31% YoY growth; Screening rev guidance $71-$73M.
Non-GAAP gross margin 66% (up from 63%); cash, equivalents and restricted cash $689.5M.
Shield expanded to multi-cancer detection; Guardant360 Liquid PMA submitted to FDA; new collaborations with Quest and PathGroup.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.